Pharmacyclics (AbbVie) Deal History & Licensing Activity
Pharmacyclics (AbbVie) is a life sciences. Over the past three years, Pharmacyclics (AbbVie) has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 2 active clinical trials, primarily in Option Deals.
Deals (12mo)
2
Active Trials
2
Top Modality
Small Molecules
Focus Area
Option Deals
Pharmacyclics (AbbVie) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Pharmacyclics (AbbVie) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Imbruvica | AbbVie | Small Molecules | Approved | co development | Jul 18, 2026 |
| next-generation CNS portfolio | AbbVie | Small Molecules | Unknown | option | Jul 18, 2026 |
Pharmacyclics (AbbVie) Pipeline Focus
Therapeutic areas and modalities where Pharmacyclics (AbbVie) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Pharmacyclics (AbbVie) Strategic Signals
Key indicators of Pharmacyclics (AbbVie)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Pharmacyclics (AbbVie) Clinical Pipeline
Pharmacyclics (AbbVie) has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 2
See How Your Asset Matches Pharmacyclics (AbbVie)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Pharmacyclics (AbbVie) Licensing & Deal Activity
Pharmacyclics (AbbVie) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Pharmacyclics (AbbVie) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Pharmacyclics (AbbVie) include Option Deals (3 deals and trials), and Codev Deals (2 deals and trials). In terms of modality, Pharmacyclics (AbbVie) has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Pharmacyclics (AbbVie) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Pharmacyclics (AbbVie)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.